P-MUC1C-ALLO1 同种异体 CAR-T 细胞治疗晚期或转移性实体瘤患者
P-MUC1C-ALLO1 在晚期或转移性实体瘤成人受试者中的 1 期剂量递增和扩展队列研究
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
研究概览
地位
详细说明
This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-MUC1C-ALLO1 to determine a Recommended Phase 2 Dose (RP2D). P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen. Additional participants will be treated with P-MUC1C-ALLO1 at the determined RP2D.
Following enrollment, subjects will be treated with P-MUC1C-ALLO1 and will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Irvine、California、美国、92868
- University of California, Irvine Medical Center
-
Los Angeles、California、美国、90048
- Cedars Sinai Medical Center
-
San Diego、California、美国、92037
- University of California, San Diego
-
San Francisco、California、美国、94143
- University of California, San Francisco
-
-
Colorado
-
Denver、Colorado、美国、80218
- Sarah Cannon Research Institute at HealthONE
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Westwood、Kansas、美国、66205
- University of Kansas Cancer Center
-
Wichita、Kansas、美国、67214
- Cancer Center of Kansas
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- University of Maryland Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Dana Farber Cancer Institute
-
-
Nebraska
-
Omaha、Nebraska、美国、68198
- University of Nebraska Medical Center
-
-
New York
-
The Bronx、New York、美国、10467
- Montefiore Medical Center
-
-
Texas
-
Houston、Texas、美国、77030
- MD Anderson Cancer Center
-
San Antonio、Texas、美国、78229
- NEXT Oncology
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Males or females, Subjects ≥18 years with life expectancy >3 months
- Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer
- Must have progressed during or after last therapy, developed intolerance/toxicity to current treatment, or ineligible or refused other existing treatment options, and have measurable disease
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%
- Must have adequate vital organ function within pre-determined parameters
- Must have archived tumor tissue available or consent to a biopsy collection
- Must be willing to practice birth control
- Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration
- Must have recovered from toxicities due to prior therapies
Exclusion Criteria:
- Has inadequate venous access
- Has an active second malignancy (not disease free for at least 5 years) in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
- Is pregnant or lactating
- Has a history of or active autoimmune disease
- Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy
- Has an active systemic (viral, bacterial, or fungal) infection
- Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia
- Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
- Has received anticancer medications within 2 weeks of the time of initiating lymphodepletion
- Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and/or expected to require them while enrolled in the study
- Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study
- Has known CNS metastases or symptomatic CNS involvement
- Has a history of significant liver disease or active liver disease
- Has a history of known genetic predisposition to HLH/MAS
- Has received anti-cancer monoclonal antibody therapy within 4 weeks of initiating LD therapy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
实验性的:P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1
大体时间:Baseline through Day 28
|
Number of subjects with a dose limiting toxicity (DLT) |
Baseline through Day 28
|
|
Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1
大体时间:Baseline through 15 years
|
Frequency and severity of adverse events |
Baseline through 15 years
|
|
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
大体时间:Baseline through 15 years
|
According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, secondarily Immune Response Evaluation Criteria in Solid Tumors (iRECIST): Overall Response Rate (ORR) |
Baseline through 15 years
|
合作者和调查者
调查人员
- 研究主任:Simon Heidegger, M.D.、Lead Medical Director, Oncology, Genentech Research Early Development
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 口腔疾病
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 男性泌尿生殖系统疾病
- 肾脏疾病
- 泌尿系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 呼吸道疾病
- 组织学类型的肿瘤
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 胃病
- 肠道肿瘤
- 直肠疾病
- 生殖器疾病,女性
- 肺部疾病
- 内分泌腺肿瘤
- 头颈肿瘤
- 胰腺疾病
- 肿瘤、腺体和上皮
- 腺癌
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 肺肿瘤
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 泌尿系肿瘤
- 癌
- 耳鼻喉科疾病
- 肾脏肿瘤
- 癌,支气管癌
- 支气管肿瘤
- 咽部肿瘤
- 耳鼻咽喉肿瘤
- 鼻咽疾病
- 咽部疾病
- 癌,鳞状细胞
- 皮肤和结缔组织疾病
- 头颈部鳞状细胞癌
- 胃肿瘤
- 结直肠肿瘤
- 卵巢肿瘤
- 乳腺肿瘤
- 胰腺肿瘤
- 癌,肾细胞
- 癌,非小细胞肺癌
- 鼻咽肿瘤
其他研究编号
- P-MUC1C-ALLO1-001
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.